1[1]Shen Z X, Chen G Q, Ni J H, et al. Use of Arsenic Trioxide (As2O3) in the Treatment of Acute Promyelocytic Leukemia: II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients. Blood, 1997, 89: 3354-3360.
2[2]Chen Z, Wang Z Y, Chen S J. Acute promyelocytic leukemia:cellular and molecular basis of differentiation and apoptosis. Pharmacol Ther, 1997, 76:141-149.
3[3]Niu C, Yan H, Yu T, et al. Studies of Treatment of Acute Pro-myelocytic Leukemia with Arsenic Trioxide: remission induction, follow-up, and molecular monitoring in 11 newly-diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood, 1999, 94:3315-3324.
5Shen Zhixiang, Chen Guoqiang, Ni Jianhua. Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia(APL): II. clinic efficacy and pharmaeokinetics in relapsed patients [J]. Blood, 1997,89(9): 3354-3360.
6Shen ZX,Chen GQ,Ni JH,et al.Use of arsenic trioxide(As2O3)in the treatment of acute promyelocytic leukemia(APL):Ⅱ.clinical efficacy and pharmacokinetics in re-lapsed patients[J].Blood,1997,89(9):3354-3360.
7Huang Y,Waxman S.Synergistic induction of apoptosis by combination cytotoxic-differentiation therapy[J].Cancer Res,1993,34:239.
8Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3 ) in the treatment of acute myelogenous leukemia: As2O3 induces NB4 cells apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR α/PML proteins. Blood, 1996,88:1052-1061.
